Shares of CRH Medical Corporation (NASDAQ:CRHM) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating. CRH Medical’s rating score has improved by 24.8% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokers have set a 1 year consensus target price of $4.94 for the company and are forecasting that the company will post ($0.01) EPS for the current quarter, according to Zacks. Zacks has also given CRH Medical an industry rank of 78 out of 256 based on the ratings given to related companies.
Separately, Bloom Burton raised CRH Medical from an “accumulate” rating to a “buy” rating in a research report on Thursday, August 1st.
CRH Medical (NASDAQ:CRHM) last released its earnings results on Wednesday, July 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.01. The firm had revenue of $30.48 million during the quarter, compared to analyst estimates of $29.50 million.
CRH Medical Company Profile
CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.
Further Reading: Diluted Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.